We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ulcerative

News List

Vedolizumab Beats Adalimumab for Ulcerative Colitis Remissions drugs
September 26, 2019
In moderate-to-severe ulcerative colitis, vedolizumab is superior to adalimumab for achieving clinical remission and endoscopic improvement ...
EC expands label of Janssen’s Stelara to include ulcerative colitis pharmaceutical-technology
September 10, 2019
Johnson & Johnson subsidiary Janssen has announced the European Commission (EC) has approved Stelara (ustekinumab) for patients with moderately to severely active ulcerative colitis (UC).
EC approves expanded use of ustekinumab for ulcerative colitis europeanpharmaceuticalreview
September 09, 2019
The biologic treatment ustekinumab has been granted an expanded use for ulcerative colitis within the EU.
Ulcerative Colitis Outcomes Similar for Smokers, Nonsmokers drugs
August 12, 2019
Smokers and nonsmokers with ulcerative colitis (UC) have similar outcomes, according to a study published online in Alimentary Pharmacology and Therapeutics.
FDA: Blood Clot, Death Risk Up With Higher Dose of Tofacitinib drugs
July 29, 2019
New warnings about an increased risk of thrombosis and of death among ulcerative colitis patients taking the 10 mg twice daily dose of the drug tofacitinib...